Madrigal Pharmaceuticals Announces FDA Approval of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Moderate to Advanced Liver Fibrosis
Rezdiffra, the first FDA-approved medication for NASH, targets liver fibrosis and NASH resolution in noncirrhotic patients with moderate to advanced liver fibrosis. Approved based on Phase 3 MAESTRO-NASH trial results, it offers a new treatment paradigm, with ongoing studies to confirm clinical benefits and support full approval.
Reference News
Madrigal Pharmaceuticals Announces FDA Approval of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Moderate to Advanced Liver Fibrosis
Rezdiffra, the first FDA-approved medication for NASH, targets liver fibrosis and NASH resolution in noncirrhotic patients with moderate to advanced liver fibrosis. Approved based on Phase 3 MAESTRO-NASH trial results, it offers a new treatment paradigm, with ongoing studies to confirm clinical benefits and support full approval.